XML 196 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other disclosures (Tables)
 12 Months Ended
Dec. 31, 2024
Additional information [abstract]  
Share-based payment expensed in the income statement
Share-based payment expensed in the income statement
DKK million202420232022
Restricted stock units to employees380365265
Long-term share-based incentive programme (Management Board)314304250
Long-term share-based incentive programme (Management group below Management Board)1,4031,271819
Restricted stock units to individual employees192209205
Share-based payment expensed in the income statement2,2892,1491,539
Outstanding restricted stock units
General terms and conditions of 2022-2024 programmes
Employees' 100 year anniversary programmeManagement BoardManagement group below
Management Board		Individual employees
Year of launch2023202420232022202420232022202420232022
Preliminary number of shares to be allocated1 (million)
3.0 0.3 0.6 0.7 1.5 3.1 3.3 0.2 0.3 0.8 
Fair value per restricted stock unit at grant date (DKK)446 767 456 320 767 456 320 794 544 371 
Performance and vesting period2023 to 20262024 to 20262023 to 20252022 to 20242024 to 20262023 to 20252022 to 20242024 to 20272023 to 20262022 to 2025
Allocation dateAug 2026Feb 2027Feb 2026Feb 2025Feb 2027Feb 2026Feb 2025202720262025
Amortisation period3.5 years3 years3 years3 years3 years3 years3 years3 years3 years3 years
1. The number of shares to be allocated under the LTIPs to Management Board and management group below Management Board, respectively, may potentially be reduced or increased depending on whether Novo Nordisk's performance during the 3-year performance period is higher or lower compared to targets determined by the Board. The maximum number is capped.
Contractual obligations not recognised in the balance sheet
Contractual obligations not recognised in the balance sheet
DKK million (undiscounted)CurrentNon-currentTotal
2024
Leases1
288 3,893 4,181
Research and development obligations12,101 23,215 35,316
Research and development – potential milestone payments2
2,076 32,507 34,583
Commercial product launch – potential milestone payments2
384 16,543 16,927
Purchase obligations relating to investments in property, plant and equipment8,305 3,354 11,659
Purchase obligations relating to contract manufacturers8,925 62,136 71,061
Other purchase obligations10,531 8,463 18,994
Total obligations not recognised
in the balance sheet		42,610 150,111 192,721
2023
Leases1
144 2,053 2,197 
Research and development obligations8,678 13,235 21,913 
Research and development – potential milestone payments2
1,234 27,311 28,545 
Commercial product launch – potential milestone payments2
— 12,952 12,952 
Purchase obligations relating to investments in property, plant and equipment4,222 1,693 5,915 
Purchase obligations relating to contract manufacturers6,315 26,792 33,107
Other purchase obligations7,151 5,888 13,039 
Total obligations not recognised
in the balance sheet		27,744 89,924 117,668 
1. Predominantly relates to estimated variable property taxes, leases committed but not yet commenced and low value leases. 2. Potential milestone payments are associated with uncertainty because they are linked to successful achievements in research activities.
Fair value of recognized assets and liabilities
Fair value recognised at date of acquisition
2024
DKK millionFill-finish sites (Catalent)Other acquisitionsTotal
Know-how41,102—41,102
Intellectual property rights and other intangible assets31152363
Property, plant and equipment24,83960825,447
Deferred tax assets (liabilities), net992(7)985
Provisions(1,084)—(1,084)
Other net assets1,290(2)1,288
Net identifiable assets acquired67,45065168,101
Goodwill15,2933015,323
Purchase price82,74368183,424
Settlement of pre-existing relationships(597)—(597)
Cash consideration transferred82,14668182,827
Cash acquired(664)—(664)
Cash used for acquisition of businesses; net of cash acquired81,48268182,163
Material transactions with related parties
Material transactions with related parties
DKK million202420232022
Novo Holdings A/S
Purchase of Novo Nordisk B shares10,1648,7756,984
Acquisition of fill-finish sites (note 5.3)82,146——
Dividend payment to Novo Holdings A/S12,5029,0287,207
Services provided by Novo Nordisk(33)(17)(24)
Novonesis Group
Services provided by Novo Nordisk(48)(48)(78)
Services provided by Novonesis11711292
Altasciences Group
Services provided by Altasciences14622970
Other subsidiaries of Novo Holding A/S
Services provided to Novo Nordisk93——
NNIT Group
Services provided by NNIT257436660
Remuneration to Executive Management and Board of Directors
Remuneration to Executive Management and Board of Directors
DKK million202420232022
Salary and short-term incentive180173141
Pension181713
Benefits1
55199
Long-term incentive2
11212197
Executive Management in total3
365330260
Fees to Board of Directors4
232220
Total388352280
1. In 2024, an amount of DKK 45.4 million relates to recruitment arrangements as well as
a conditional amount payable at the end of employment. 2. Refer to note 5.1 for further
information on share-based payment schemes. 3. Total remuneration for persons registered as members of Executive Management with the Danish Business Authority amounts to DKK 88 million (DKK 195 million in 2023 and DKK 175 million in 2022). 4. All members of the Board of Directors
are registered with the Danish Business Authority.
Fee to statutory auditors
DKK million202420232022
Statutory audit1
353038
Audit-related services532
Tax advisory services983
Other services131812
Total fees to statutory auditors625955
1. Statutory audit fees in 2024 include DKK 5 million of additional fees mainly related to business acquisitions. Statutory audit fees in 2022 include DKK 9 million of additional fee related to 2021.
Companies in the Novo Nordisk Group
Company and countryActivity
Parent company
Novo Nordisk A/S, Denmark••••
Subsidiaries by geographical area
Company and countryPercentage of shares ownedActivity
North America Operations
Inversago Pharma Inc., Canada100•
Novo Nordisk Canada Inc., Canada100•
Novo Nordisk North America Operations A/S, Denmark100•
Novo Nordisk Inc., US100•
Novo Nordisk Pharmaceutical Industries LP, US100•
Novo Nordisk Pharmatech US, Inc., US100•
Novo Nordisk Pharma, Inc., US100•
NN Corporate Development US, Inc., US100•
NN Research & Development US, Inc., US100•
Novo Nordisk US Bio Production, Inc., US100•
Novo Nordisk US Holdings Inc., US100•
Dicerna Pharmaceuticals, Inc., US100•
Emisphere Technologies, Inc., US100•
Forma Therapeutics, Inc., US100•
Catalent Indiana LLC, US 100•
Region International Operations
Novo Nordisk Pharmaceuticals A/S, Denmark100•
Novo Nordisk Pharma Operations A/S, Denmark100••
Novo Nordisk Region AAMEO and LATAM A/S, Denmark100•
Novo Nordisk Region Europe A/S, Denmark100•
Novo Nordisk Region Japan & Korea A/S, Denmark100•
Region EMEA
Aldaph SpA, Algeria100••
Novo Nordisk Pharma GmbH, Austria100•
S.A. Novo Nordisk Pharma N.V., Belgium100•
Catalent Belgium S.A, Belgium 100•
Novo Nordisk Pharma d.o.o., Bosnia and Herzegovina100•
Novo Nordisk Pharma EAD, Bulgaria100•
Novo Nordisk Hrvatska d.o.o., Croatia100•
Novo Nordisk s.r.o., Czech Republic100•
Novo Nordisk Production Czech s.r.o, Czech Republic100•
Novo Nordisk Denmark A/S, Denmark100•
Novo Nordisk Pharmatech A/S, Denmark100••
Novo Nordisk Egypt LLC, Egypt100•
Novo Nordisk Egypt Pharmaceuticals Ltd., Egypt100•
Company and countryPercentage of shares ownedActivity
Novo Nordisk Estonia OÜ, Estonia100•
Novo Nordisk Farma OY, Finland100•
Biocorp Production S.A., France100••
Novo Nordisk, France100•
Novo Nordisk Production SAS, France100•
Novo Nordisk Pharma GmbH, Germany100•
Cardior Pharmaceuticals GmbH, Germany100•
Novo Nordisk Hellas Epe., Greece100•
Novo Nordisk Hungária Kft., Hungary100•
Novo Nordisk Limited, Ireland100•
Novo Nordisk Production Ireland Ltd., Ireland100•
Novo Nordisk Ltd, Israel100•
Novo Nordisk S.P.A., Italy100•
Catalent Anagni S.R.L, Italy100•
Novo Nordisk Kazakhstan LLP, Kazakhstan100•
Novo Nordisk Kenya Ltd., Kenya100•
Novo Nordisk Latvia SIA, Latvia100•
Novo Nordisk Pharma SARL, Lebanon100•
UAB Novo Nordisk Pharma, Lithuania100•
Novo Nordisk Farma dooel, North Macedonia100•
Novo Nordisk Pharma SAS, Morocco100•
Novo Nordisk B.V., Netherlands100•
Novo Nordisk Finance (Netherlands) B.V., Netherlands100•
Novo Nordisk Pharma Limited, Nigeria100•
Novo Nordisk Norway AS, Norway100•
Novo Nordisk Pharmaceutical Services Sp. z.o.o., Poland100•
Novo Nordisk Pharma Sp.z.o.o., Poland100•
Novo Nordisk Portugal, Lda., Portugal100•
Novo Nordisk Farma S.R.L., Romania100•
Novo Nordisk Limited Liability Company, Russia100••
Novo Nordisk Production Support LLC, Russia100•
Novo Nordisk Saudi for Trading, Saudi Arabia100•
Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Serbia100•
Novo Nordisk Slovakia s.r.o., Slovakia100•
Novo Nordisk, d.o.o., Slovenia100•
Novo Nordisk (Pty) Limited, South Africa100•
Novo Nordisk Pharma S.A., Spain100•
Novo Nordisk Scandinavia AB, Sweden100•
Novo Nordisk Health Care AG, Switzerland100•••
Novo Nordisk Pharma AG, Switzerland100•
Novo Nordisk Tunisie SARL, Tunisia100•
Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Turkey100•
Novo Nordisk Ukraine, LLC, Ukraine100•
Novo Nordisk Pharma Gulf FZE, United Arab Emirates100•
Novo Nordisk Limited, UK100•
Novo Nordisk Research Centre Oxford Limited, UK100•
Company and countryPercentage of shares ownedActivity
Region China
Novo Nordisk (China) Pharmaceuticals Co. Ltd., China100••
Novo Nordisk (Shanghai) Pharma Trading Co., Ltd., China100•
Novo Nordisk Region China A/S, Denmark100•
Novo Nordisk Hong Kong Limited, Hong Kong100•
Novo Nordisk Pharma (Taiwan) Ltd., Taiwan100•
Beijing Novo Nordisk Pharmaceuticals Science & Technology Co., Ltd., China100•
Region Rest of World
Novo Nordisk Pharma Argentina S.A., Argentina100•
Novo Nordisk Pharmaceuticals Pty. Ltd., Australia100•
Novo Nordisk Pharma (Private) Limited, Bangladesh100•
Novo Nordisk Produção Farmacêutica do Brasil Ltda., Brazil100•
Novo Nordisk Farmacêutica do Brasil Ltda., Brazil100•
Novo Nordisk Farmacéutica Limitada, Chile100•
Novo Nordisk Colombia SAS, Colombia100•
Novo Nordisk India Private Limited, India100•
Novo Nordisk Service Centre (India) Pvt. Ltd., India100•
PT. Novo Nordisk Indonesia, Indonesia100•
Novo Nordisk Pars Co. (PJS), Iran100••
Novo Nordisk Pharma Ltd., Japan100••
Novo Nordisk Pharma (Malaysia) Sdn Bhd, Malaysia100•
Novo Nordisk Pharma Operations Sdn Bhd, Malaysia100•
Novo Nordisk Mexico S.A. de C.V., Mexico100•
Novo Nordisk Service Centre Mexico, Sociedad Anonim, Mexico100•
Novo Nordisk Pharmaceuticals Ltd., New Zealand100•
Novo Nordisk Pharma (Private) Limited, Pakistan100•
Novo Nordisk Panama S.A., Panama100•
Novo Nordisk Peru S.A.C., Peru100•
Novo Nordisk Pharmaceuticals (Philippines) Inc., Philippines100•
Novo Nordisk Pharma (Singapore) Pte Ltd., Singapore100•
Novo Nordisk Pharma Korea Ltd., South Korea100•
Novo Nordisk Lanka (PVT) Ltd, Sri Lanka100•
Novo Nordisk Pharma (Thailand) Ltd., Thailand100•
Novo Nordisk Vietnam Ltd., Vietnam100•
Other subsidiaries and associated companies
NNE A/S, Denmark100•
NNIT A/S, Denmark18 •
CS Solar Fund XIV, LLC, US99 •
Companies without significant activities are not included in the list.
NNE A/S subsidiaries are not included in the list.